Table 3.
Sympercent change in urine AKI biomarkers across study time points between patients with and without CKD and hypertension at 3 months post-cisplatin
| Timepoint | 3 mo | |
|---|---|---|
| Median (IQR), n | Median (IQR), n | |
| NGAL, ng/mg creatinine | ||
| CKD | No CKD | |
| EV post—pre | 8.18 (−61.75 to 70.01), 46 | −12.23 (−68.91 to 46.41), 63 |
| EV DC—pre | 30.86 (−25.93 to 87.66), 44 | 7.95 (−48.38 to 66.92), 60 |
| LV post—pre | 21.38 (−132.64 to 99.03), 34 | 0.00 (−104.52 to 52.11), 51 |
| LV DC—pre | 27.31 (−95.05 to 85.80), 32 | 0.84 (−104.16 to 59.27), 46 |
| LV post—EV pre | 7.21 (−59.54 to 81.60), 37 | −18.38 (−93.66 to 54.48), 51 |
| LV DC—EV pre | 13.65 (−86.18 to 86.50), 34 | −11.09 (−122.89 to 95.64), 47 |
| HTN | No HTN | |
| EV post—pre | 25.15 (−37.96 to 46.48), 17 | −12.25 (−68.08 to 50.10), 100 |
| EV DC—pre | 30.31 (−27.88 to 130.58), 15 | 24.87 (−48.38 to 76.86), 96 |
| LV post—pre | 8.63 (−92.97 to 99.03), 11 | 3.37 (−104.52 to 62.27), 83 |
| LV DC—pre | 48.92 (−116.41 to 145.33), 10 | 3.74 (−93.98 to 62.96), 80 |
| LV post—EV pre | 27.41 (−63.66 to 81.60), 13 | −13.14 (−83.48 to 74.54), 82 |
| LV DC—EV pre | 38.59 (−7.13 to 90.83), 12 | −15.71 (−121.87 to 79.19), 79 |
| KIM-1, pg/mg creatinine | ||
| CKD | No CKD) | |
| EV post—pre | −16.08 (−122.85 to 52.40), 46 | −18.23 (−115.64 to 34.89), 63 |
| EV DC—pre | 104.68 (2.11–222.40), 44 | 82.83 (−1.86 to 183.53), 60 |
| LV post—pre | 12.44 (−56.43 to 69.65), 34 | −28.17 (−74.65 to 44.89), 51 |
| LV DC—pre | 125.31 (24.81–170.53), 32 | 82.97 (−3.61 to 197.09), 46 |
| LV post—EV pre | 1.37 (−104.67 to 120.18), 37 | −0.63 (−85.05 to 39.03), 51 |
| LV DC—EV pre | 105.82 (1.29–223.80), 34 | 119.30 (0.00–224.82), 47 |
| HTN | No HTN | |
| EV post—pre | 58.22 (4.00–115.57), 17 | −28.28 (−127.00 to 21.52)a, 100 |
| EV DC—pre | 244.17 (−43.15 to 363.26), 15 | 101.67 (4.51–183.53), 96 |
| LV post—pre | 63.60 (−28.17 to 116.15), 11 | −21.38 (−71.00 to 57.06), 83 |
| LV DC—pre | 146.80 (108.24–242.05), 10 | 101.25 (2.63–162.42), 80 |
| LV post—EV pre | 120.18 (−1.97 to 265.36), 13 | −3.34 (−85.05 to 51.61)a, 82 |
| LV DC—EV pre | 170.02 (78.03–382.91), 12 | 108.26 (1.29–194.16), 79 |
| TIMP-2×IGFPB-7, (ng/ml) 2 /1000 | ||
| CKD | No CKD | |
| EV post—pre | −158.67 (−334.57 to −28.15), 49 | −216.91 (−379.92 to −27.75), 66 |
| EV DC—pre | −23.79 (−184.16 to 140.34), 47 | −43.78 (−326.85 to 178.77), 63 |
| LV post—pre | −88.59 (−214.34 to 57.35), 37 | −267.03 (−408.72 to −101.48)a, 51 |
| LV DC—pre | 48.66 (−210.32 to 193.02), 35 | −173.15 (−327.23 to 58.77)a, 47 |
| LV post—EV pre | −129.01 (−330.18 to 79.41), 40 | −156.72 (−386.79 to −2.66), 52 |
| LV DC—EV pre | −69.79 (−220.89 to 174.36), 38 | −64.87 (−316.26 to 114.73), 48 |
| HTN | No HTN | |
| EV post—pre | −84.27 (−356.05 to −2.18), 17 | −210.39 (−370.18 to −44.69), 106 |
| EV DC—pre | 132.43 (−88.69 to 342.27), 16 | −72.38 (−294.39 to 151.56)a, 101 |
| LV post—pre | −47.37 (−183.49 to 121.16), 11 | −195.54 (−351.76 to 43.02), 86 |
| LV DC—pre | 70.78 (−181.37 to 185.24), 10 | −93.53 (−289.64 to 155.23), 83 |
| LV post—EV pre | 60.36 (−154.07 to 122.34), 13 | −155.29 (−384.4 to −28.04)a, 86 |
| LV DC—EV pre | 65.97 (−128.06 to 243.54), 12 | −104.74 (−281.63 to 110.96)a, 83 |
Results stratified by time of cisplatin infusion. DC, near hospital discharge; EV, early visit; HTN, hypertension; IGFBP-7, insulin-like growth factor-binding protein 7; IQR, interquartile range; KIM-1, kidney injury molecule-1; LV, late visit; NGAL, neutrophil gelatinase-associated lipocalin; Pre, pre-cisplatin infusion; Post, post-cisplatin infusion; TIMP-2, tissue inhibitor of metalloproteinase-2.
a
Stands for significant difference between Outcome and No Outcome groups by Mann–Whitney U Test: P < 0.05.